The largest global research initiative aimed at tackling the challenge of neurodegenerative diseases.
Arabic (Arabic )
Bulgarian (Bulgarian)
Croatian (Croatian)
Danish (Danish)
Dutch (Dutch)
French (French)
Finnish (Finnish)
German (German)
Greek (Greek)
Hebrew (Hebrew)
Hungarian (Hungarian)
Italian (Italian)
Norwegian (Norwegian)
Polish (Polish)
Portuguese (Portuguese)
Romanian (Romanian)
Slovak (Slovak)
Slovenian (Slovenian)
Spanish (Spanish)
Swedish (Swedish)
Turkish (Turkish)
Data Hubs
Global Cohort Portal
Experimental Models for Parkinson's Disease
Home » Research News (General) » Existing compound holds promise for reducing Huntington's disease progression
Existing compound holds promise for reducing Huntington's disease progression
Researchers have discovered that an existing compound, previously tested for diabetes, offers hope for slowing Huntington's Disease (HD) and its symptoms.
The study was published in Nature Medicine.
"We're very excited by our pre-clinical testing of this compound (KD3010)," said Albert La Spada, MD, PhD, professor of pediatrics, cellular and molecular medicine and neurosciences at UC San Diego School of Medicine. "It improved motor function, reduced neurodegeneration and increased survival in a mouse model of Huntington's disease and reduced toxicity in neurons generated from human HD stem cells."
The discovery of the drug's potential in HD builds upon more than a decade of research into the disorder's underlying molecular pathology. Much of that work has centered on misfolded proteins, which are known to be key culprits in HD and several other neurodegenerative diseases.
At the cellular level, the drug improved mitochondrial energy production and helped mice get rid of the misfolded proteins. Since misfolded proteins also underlie Alzheimer's, Parkinson's and other neurodegenerative disorders, researchers hope that, if successful in HD, the compound can also be tested in other related neurological diseases.
Source: UC San Diego
"PPAR-δ is repressed in Huntington's disease, is required for normal neuronal function and can be targeted therapeutically"
Research News (General)
GO TO JPND NEWS GO TO RESEARCH NEWS GO TO INTERVIEWS
Newsletter / RSS Signup
JPND News
JPND Press Releases
JPND Progress
JPND Publications
Aging Alzheimer's Alzheimer's disease Brain Brain research Dementia neurodegeneration Parkinson's Parkinson's Disease Research
There are no post to show.
VIEW ALL JPND NEWS & MEDIA
The EU Joint Programme – Neurodegenerative Disease Research (JPND) is the largest global research initiative aimed at tackling the challenge of neurodegenerative diseases, in particular, Alzheimer's.
Tweets by @JPNDeurope
This initiative has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreements No. 643417, No. 681043 and No. 825664.
©2019 JPND Research | Web Design & Support by AGENT Digital | Privacy Policy | Cookie Policy